Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia
暂无分享,去创建一个
Chun Xing Li | Jing Wang | Fang Cao | Wenxiu Lv | Liang Wang | Tianping Chen | Shen Wang | Na Li | Li Chen | Bo Zhang | Fang Xv | Chenglin Liao | Hong-Jie Liu
[1] Ping Wang,et al. [Clinical Analysis of Pediatric Acute Myeloid Leukemia with CCLG-AML 2015 Regimen]. , 2022, Zhongguo shi yan xue ye xue za zhi.
[2] Liang Wang,et al. Analysis of efficacy, safety and prognostic factors of DAC-HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia , 2021, Molecular and clinical oncology.
[3] J. Serody,et al. Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. , 2021, Blood cancer discovery.
[4] Xiaojuan Chen,et al. Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy , 2021, Cancer medicine.
[5] R. Taplitz,et al. Updates in infection risk and management in acute leukemia. , 2020, Hematology. American Society of Hematology. Education Program.
[6] S. Shen,et al. The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China , 2020, Pediatric hematology and oncology.
[7] C. Nair,et al. Infection at diagnosis—a unique challenge in acute myeloid leukemia treatment in developing world , 2020, Supportive Care in Cancer.
[8] R. Rau,et al. The genomics of acute myeloid leukemia in children , 2020, Cancer and Metastasis Reviews.
[9] Diana Lagana,et al. Bloodstream infections in neutropenic patients with haematological malignancies. , 2020, Infection, disease & health.
[10] R. Aplenc,et al. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. , 2019, Current opinion in pediatrics.
[11] Jun Wang,et al. High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing. , 2019, Biomaterials.
[12] M. Viana,et al. Cytogenetic abnormalities, WHO classification, and evolution of children and adolescents with acute myeloid leukemia , 2019, Hematology, transfusion and cell therapy.
[13] Y. Nakazawa,et al. Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia , 2018, Bone Marrow Transplantation.
[14] A. Mansour,et al. Treatment outcomes of children with acute lymphoblastic leukemia in a middle-income developing country: high mortalities, early relapses, and poor survival , 2018, Jornal de pediatria.
[15] Beth Wilmot,et al. Functional Genomic Landscape of Acute Myeloid Leukemia , 2018, Nature.
[16] F. Chong,et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time , 2017, Nature Communications.
[17] J. Cortes,et al. Treatment of Relapsed/Refractory Acute Myeloid Leukemia , 2017, Current Treatment Options in Oncology.
[18] G. Lucchini,et al. Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience , 2015, Bone Marrow Transplantation.
[19] S. Jaiswal,et al. Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Donor Lymphocyte Infusions. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] P. Marik,et al. A Descriptive Study , 2015 .
[21] S. Raimondi,et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Hong-guo Zhao,et al. [Prospective multicentre study of chemotherapeutic regimen containing pirarubicin on the treatment of relapsed or refractory acute myeloid leukemia in adults]. , 2014, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.
[23] S. Davies,et al. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. , 2014, Blood.
[24] Krister Wennerberg,et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. , 2013, Cancer discovery.
[25] E. Steliarova-Foucher,et al. New policies to address the global burden of childhood cancers. , 2013, The Lancet. Oncology.
[26] T. Renaud,et al. Relapsed and Refractory Pediatric Acute Myeloid Leukemia: Current and Emerging Treatments , 2013, Pediatric Drugs.
[27] D. Reinhardt,et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report , 2012, Leukemia.
[28] R. Rihani,et al. Outcome of childhood acute lymphoblastic leukemia in Jordan , 2011, Pediatric blood & cancer.
[29] Eva Steliarova-Foucher,et al. Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study. , 2008, The Lancet. Oncology.
[30] R. Schlenk,et al. Significance of age in acute myeloid leukemia patients younger than 30 years , 2008, Cancer.
[31] R. Hanada,et al. Repetitive cycles of high‐dose cytarabine are effective for childhood acute myeloid leukemia: Long‐term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group , 2007, Pediatric blood & cancer.
[32] C. Pui,et al. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia , 2007, Cancer.
[33] U. Creutzig,et al. Pediatric acute myeloid leukemia: international progress and future directions , 2005, Leukemia.
[34] G. Specchia,et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience , 2003, Annals of Hematology.
[35] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[36] P. Huxley. A UK experience. , 1998, Canadian journal of community mental health = Revue canadienne de sante mentale communautaire.
[37] Unión,et al. Bortezomib/Cyclophosphamide/Dexamethasone Regimen , 2020, Definitions.